The widespread use of thalidomide, a drug that had been prescribed to pregnant women during the 1950’s as a sleep aid and as relief from morning sickness, led to birth disorders among thousands of children around the globe. Inadequate, although standard, testing for the time, along with aggressive marketing, produced an epidemic. The U.S. Food and Drug Administration, which disallowed the drug’s use in the United States, would increase its regulations on drug testing and approval soon after the scandal.
During the early 1950’s, a Swiss pharmaceutical company had synthesized the drug
A child born with a disability caused by the prescription drug thalidomide writes with the aid of a pencil-holding device.
The first so-called thalidomide baby was born in 1956, one year before the drug’s initial widespread marketing. The years that followed witnessed a dramatic increase in the number of babies born with birth disorders, including deafness, cleft palate, blindness, and, characteristic of thalidomide babies, torsos without arms, legs, or both. Some babies also had “flipperlike” limbs that grew from the shoulder or hip. Eventually, physicians and researchers were able to link these birth disorders to the thalidomide taken by women while they were pregnant.
No accurate census of children that had been affected by the drug exists, but approximately five thousand thalidomide cases have been documented. It is known that thalidomide affected thousands of children worldwide. There also may have been thousands of stillborn or miscarried fetuses, and an estimated 40 percent of those born with the disorders died before their first birthday.
Grünenthal continued research and development during 1954 and for the next few years. The company marketed the drug as an anticonvulsant for epilepsy, but it was subsequently proved ineffective. However, thalidomide was found to be effective as a sedative or sleep aid. In particular, those targeted for its use were women experiencing nausea and morning sickness during pregnancy. Three years later, in October, 1957, thalidomide was marketed for morning sickness and nausea and soon became the drug of choice to help pregnant women with these symptoms. Thalidomide went into general use by 1958 and was widely prescribed around the world.
An American pharmacologist, Frances Oldham Kelsey, looked into the effects of the drug. As a U.S. Food and Drug Administration (FDA) drug evaluator, she repeatedly held off numerous efforts by a U.S.-based licensee of
Because thalidomide did not receive FDA approval in the United States, fewer American women gave birth to thalidomide babies. Women in the United States who were affected had obtained the drug while living abroad or had participated in earlier studies. In recognition of her critical work, Kelsey was awarded the President’s Award for Distinguished Civilian Service by U.S. president John F. Kennedy in 1962.
Widukind Lenz, a German pediatrician, established a firm connection between the use of the drug by pregnant women and the birth disorders in November, 1961. He demanded that the drug be taken off the market in Germany; it was removed beginning November 27. Soon, other countries followed. Criminal indictments of nine Grünenthal employees came in 1968, and the criminal case settled two years later with a monetary settlement for those affected by the drug.
In 1972, following the criminal trial, the German government enacted a law that formed the Hilfswerk für Behinderte Kinder
Thalidomide was produced by Grünenthal until 2003, but, according to the company, it was made for humanitarian purposes only. However, the drug—made by drug companies other than Grünenthal—remains available in some countries, especially in the developing world, both legally and illegally. It is available in the United States to treat certain forms of leukemia.
Given the scandal of the 1950’s and 1960’s, the drug’s continued use remains controversial. Thalidomide was approved by the FDA in 1998 for use in the United States as a treatment for leprosy, but with very strict controls. Modern research shows that it might be effective in some cases of macular degeneration, HIV-AIDS, and multiple myeloma. FDA controls on thalidomide include the following: Doctors prescribing and pharmacists dispensing thalidomide are required to participate in a program sponsored by the drug’s manufacturer, and patients also must be educated about the drug’s effects; women must be tested for pregnancy before beginning use of the drug and tested again after use; women who use the drug must use two forms of birth control if sexually active; men taking thalidomide also must use birth control, such as a condom, because it is not known if thalidomide can produce disorders in the children they help to conceive; and donating blood or semen, as well as breast feeding, are prohibited while taking the drug.
There are several ways to measure the impact of the thalidomide scandal. To those persons and their families directly affected by the drug, the economic and emotional effects have been severe and long lasting. Many thalidomide babies who have survived into middle age and beyond have suffered further medical problems, possibly due to initial exposure to the drug in the womb.
Even more devastating has been the knowledge that the disorders could have been prevented had the drug been tested before being placed on the market. As a consequence of the scandal, the U.S. Congress in 1962 passed the Kefauver-Harris Amendment
-
Hilts, Philip J. Protecting America’s Health: The FDA, Business, and One Hundred Years of Regulation. New York: Alfred A. Knopf, 2003. Documents the history of the U.S. Food and Drug Administration from its establishment during Theodore Roosevelt’s presidency to the beginning of the twenty-first century. Emphasizes the FDA’s regulatory role and its battles against entrenched business interests. -
Knightley, Phillip, et al. Suffer the Children: The Story of Thalidomide. New York: Viking Press, 1979. Dramatic and well-written account of the development of thalidomide by Grünenthal, its medical testing, and the massive international repercussions of the thalidomide controversy. Includes appendix summarizing applicable scientific research. -
McCredie, Janet. Beyond Thalidomide: Birth Defects Explained. London: Royal Society of Medicine Press, 2007. Explores drug-induced birth disorders, with a focus on thalidomide use and its ramifications for pregnant women. -
Pray, W. Steven. A History of Nonprescription Product Regulation. Binghamton, N.Y.: Pharmaceutical Products Press, 2003. Study of over-the-counter drug regulation in the United States. Includes a chapter on the Kefauver-Harris Amendment of 1962. -
Stephens, Trent, and Rock Brynner. Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine. New York: Perseus, 2001. This book was prompted by the return of the use of thalidomide in the United States. A collaboration by a scientist (Stephens) and a novelist-historian (Brynner) carefully relates the history of the drug’s development, early uses, and later research and development. -
Wallace, Marjorie, and Michael Robson. On Giant’s Shoulders: The Story of Terry Wiles. London: Times Books, 1976. This book, later made into a film with the same title, chronicles the life of Terry Wiles, a New Zealander who was born disabled as a result of his mother taking thalidomide during pregnancy.
Alberta Government Sterilizes Thousands Deemed Genetically and Mentally Unfit
Prescription Elixir Causes More than One Hundred Deaths
Dalkon Shield Contraceptive Is Removed from the Market
Love Canal Residents Sue Chemical Company
Stephen Breuning Pleads Guilty to Medical Research Fraud
Canadian Health Commissioner Releases Report on Tainted Blood
Quebec Offers Support for Abused Duplessis Orphans
American Scientists Are Accused of Starting a Measles Epidemic in the Amazon
Liverpool Children’s Hospital Collects Body Parts Without Authorization
Immunologist Resigns After Being Accused of Falsifying Research
Manufacturer Recalls Pet Food That Killed Thousands of American Pets